Since April, Stefanie Richter has joined the company’s management team. Together with Sven Schimansky-Wabra, they will set sail for the future.
Strausberg, April 19th, 2023.
DERMAGO GmbH announced today the strengthening of its management team and the addition of experienced financial expert Stefanie Richter.
Additional services through the laboratory, sharpened strategic alignment: DERMAGO GmbH is on a growth trajectory and has brought additional expertise on board. With Stefanie Richter and Sven Schimansky-Wabra, two managing directors now jointly lead the fortunes of the DERMAGO Group.
Sven Schimansky-Wabra says: “The entire DERMAGO team warmly welcomes Stefanie Richter. After planning our new laboratory in Strausberg and applying for approval from the state authority, we want to continue growing with new projects. Stefanie will lead us with her many years of expertise in the financial sector in aligning and financing our growth strategy.”
In the future, Sven Schimansky-Wabra will be responsible for strategy, operational planning, product development, and laboratory services. His new partner, Stefanie Richter, will take over finance, controlling, personnel, and administration.
Stefanie Richter has gained her high level of professional experience in many positions and brings more than 15 years of experience in finance & controlling as well as personnel management. Most recently, she was responsible for the commercial management of a medium-sized company in Brandenburg.
Stefanie Richter explains the change: “DERMAGO has steadily grown and developed very well in recent years. Now, the next steps in development are ahead. I am excited to be part of this future.”
The DERMAGO Group includes:
Skin Care Pharma GmbH with Skinatan® as the first generic approval for Advantan®, a prescription drug for the indications of atopic dermatitis and psoriasis in individual countries.
DEGODE Pharma GmbH with Beloren® as the first generic development for the prescription originator product Skinoren/Finacea, approved for acne/rosacea indications.
As well as:
Aresus Pharma GmbH with Veregen®, a patented, prescription-only original product approved for the indication of condylomata acuminata caused by HPV viruses.